DermatologyInvestigational

Vialox (Pentapeptide-3)

Topical

Overview

Vialox is a synthetic pentapeptide designed to modulate neuromuscular signaling by interfering with acetylcholine receptor activation. The exact sequence is proprietary, but the peptide is marketed as a topical agent to reduce muscle contraction intensity in areas prone to dynamic wrinkles.

Mechanism of Action

It is positioned alongside other neuromodulating peptides as a non-invasive alternative to botulinum toxin..

Research Summary & Key Findings

Manufacturer-provided data suggest that pentapeptide-3 can reduce muscle contraction frequency in ex vivo tissue models. Small cosmetic trials have reported subjective improvements in expression line severity after 28 days, though methodological details and independent replication are lacking. No studies in indexed dermatology or pharmacology journals have validated clinical efficacy or safety profiles.

Clinical Status

Investigational

Vialox (Pentapeptide-3) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Topical

Related Peptides in Dermatology

Find a Provider

Find a verified provider who offers Vialox (Pentapeptide-3) therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Vialox (Pentapeptide-3).

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.